DFDA

Tenofovir alafenamide (TAF)

Treatment for Acute Hepatitis B

Typical Dosage: 25 mg orally once daily

Effectiveness
85%
Safety Score
72%
Clinical Trials
2
Participants
400

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
72
DangerousModerateSafe
Treatment Details
Dosage Range
25 mg orally once daily
Time to Effect
2-4 weeks for initial viral response, clinical improvement varies
Treatment Duration
Variable, typically 6-12 months post HBsAg seroconversion or longer in severe cases
Evidence Quality
HIGH
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$18,000
Monitoring:$750
Side Effect Mgmt:$100
Total Annual:$18,850
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$23,562
Cost per Remission
$26,928
Comparison vs Tenofovir disoproxil fumarate
Cost Difference
+$17,150/year
More expensive
QALY Difference
0.00 QALYs
Same outcomes
Dominance
No dominance
Prescription Access Economics
Annual Societal Loss per Patient
$14,860
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$500/year
Time Cost
$120/year
Travel + wait time
Insurance Admin Cost
$240/year
Prior auth, claims
Rx Price
$18,000/year
Potential OTC Price
$4,000/year
Estimated if OTC available
Early Treatment Benefit
+0.00 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOW
Missed Diagnosis Risk
LOW
Requires Monitoring
Yes
Needs lab work/checkups
Tenofovir alafenamide (TAF) Outcomes

for Acute Hepatitis B

Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+80%
Remission Rate
+70%
Common Side Effects
Nausea
+7%
Headache
+5%
Diarrhea
+3%
Abdominal pain
+3%
Renal impairment (less common than TDF)
+0.5%
Bone mineral density loss (less common than TDF)
+0.5%

Sources:

frontiersin.org
nih.gov
researchgate.net

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
1 active trial recruiting for Tenofovir alafenamide (TAF) in Acute Hepatitis B

Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF

NCT03920618RECRUITINGNA
View Study
150 participants
INTERVENTIONAL
Guangzhou, China
Started: Feb 21, 2019